XTLB vs. EDSA, KPRX, NNVC, TRAW, VBIV, COCP, IMNN, MNPR, TNXP, and ORGS
Should you be buying XTL Biopharmaceuticals stock or one of its competitors? The main competitors of XTL Biopharmaceuticals include Edesa Biotech (EDSA), Kiora Pharmaceuticals (KPRX), NanoViricides (NNVC), Traws Pharma (TRAW), VBI Vaccines (VBIV), Cocrystal Pharma (COCP), Imunon (IMNN), Monopar Therapeutics (MNPR), Tonix Pharmaceuticals (TNXP), and Orgenesis (ORGS). These companies are all part of the "pharmaceutical preparations" industry.
XTL Biopharmaceuticals (NASDAQ:XTLB) and Edesa Biotech (NASDAQ:EDSA) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their dividends, analyst recommendations, profitability, media sentiment, earnings, community ranking, risk, institutional ownership and valuation.
In the previous week, XTL Biopharmaceuticals and XTL Biopharmaceuticals both had 1 articles in the media. XTL Biopharmaceuticals' average media sentiment score of 0.00 equaled Edesa Biotech'saverage media sentiment score.
Edesa Biotech has a consensus price target of $39.00, indicating a potential upside of 782.35%. Given Edesa Biotech's higher probable upside, analysts plainly believe Edesa Biotech is more favorable than XTL Biopharmaceuticals.
XTL Biopharmaceuticals has a beta of 1.21, meaning that its stock price is 21% more volatile than the S&P 500. Comparatively, Edesa Biotech has a beta of 0.32, meaning that its stock price is 68% less volatile than the S&P 500.
4.4% of XTL Biopharmaceuticals shares are owned by institutional investors. Comparatively, 5.5% of Edesa Biotech shares are owned by institutional investors. 29.0% of XTL Biopharmaceuticals shares are owned by insiders. Comparatively, 25.0% of Edesa Biotech shares are owned by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company is poised for long-term growth.
XTL Biopharmaceuticals received 54 more outperform votes than Edesa Biotech when rated by MarketBeat users. However, 75.76% of users gave Edesa Biotech an outperform vote while only 71.82% of users gave XTL Biopharmaceuticals an outperform vote.
XTL Biopharmaceuticals' return on equity of -73.05% beat Edesa Biotech's return on equity.
Summary
XTL Biopharmaceuticals beats Edesa Biotech on 6 of the 10 factors compared between the two stocks.
Get XTL Biopharmaceuticals News Delivered to You Automatically
Sign up to receive the latest news and ratings for XTLB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding XTLB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
XTL Biopharmaceuticals Competitors List
Related Companies and Tools
